Myriad Genetics to Present at the 2015 Goldman Sachs Healthcare Conference
Get Alerts MYGN Hot Sheet
Join SI Premium – FREE
SALT LAKE CITY, May 28, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the Goldman Sachs Healthcare Conference at 10:40 a.m. Pacific on June 9, 2015, at the Terranea Resort in Rancho Palos Verdes, California.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad's website at www.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad is focused on strategic directives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, as well as to expand internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G
CONTACT: Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]Source: Myriad Genetics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Breezeline Supports “Cinema Columbus Film Festival”
- Earth Day 2024: How KFC is Championing Sustainability
- Santiago, Chile Will Host the 2027 Special Olympics World Games
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!